Infliximab (an anti-TNF alpha) appears to produce IBD remission and reduce proteinuria from secondary amyloidosis, and while it does not reverse the renal damage as measured by serum creatinine, it seems to stop the progression of chronic kidney disease [42]. The gene discussed is TNF; the disease is inflammatory bowel disease.